文献速递前列腺癌

Stockholm3血检联合多参数MRI用于前列腺癌诊断

Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
PubMed 文献 · Eur Urol · 2018-07-09

一项前瞻性多中心配对诊断研究纳入532名45-74岁接受前列腺癌检查的男性,评估Stockholm3血检联合MRI靶向活检的诊断性能。结果显示,仅对Stockholm3预测风险>10%的男性进行靶向和系统活检,可减少62%的活检操作,检出58%的GG1疾病,并提高GG≥2检测的相对敏感性(RS 1.10)。

要点

  • Stockholm3联合MRI靶向活检可减少活检操作并降低过度检测。
  • 仅对Stockholm3风险>10%者活检,GG≥2检测相对敏感性提高(RS 1.10)。
  • 仅对Stockholm3升高者行靶向+系统活检,GG≥2检出略降(RS 0.92)。

核心结论

  • Stockholm3血检联合MRI靶向活检策略可用于指导活检决策。

研究设计与样本

  • 前瞻性、多中心、配对诊断研究,纳入532名45-74岁接受前列腺癌检查的男性。

主要发现

  • 靶向和系统活检分别检出170例和162例GG≥2肿瘤(RS 1.05,95%CI 0.96-1.14)。
  • 仅对Stockholm3预测GG≥2风险>10%者行靶向和系统活检,需62%(95%CI 58-66)的活检操作,检出58%(95%CI 48-70)的GG1疾病,GG≥2检测相对敏感性增加(RS 1.10,95%CI 1.02-1.17)。
  • 仅对Stockholm3升高者行靶向活检,结果仅轻微改变。
  • 仅对Stockholm3升高者行靶向和系统活检,GG≥2检出略降(RS 0.92,95%CI 0.88-0.95)。

关键数值与推荐

  • Stockholm3预测GG≥2风险>10%作为活检决策阈值。
  • 相对敏感性(RS)用于比较不同活检策略的检出率。

临床怎么用

  • 可采用Stockholm3血检联合MRI靶向活检策略,减少不必要的活检并维持高级别癌检出。

局限性

  • 缺乏真实疾病患病率数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More specific diagnostic for prostate cancer is needed to decrease overdetection and number of diagnostic procedures. OBJECTIVE: To assess the performance of combining a blood-based biomarker panel and magnetic resonance imaging (MRI)-targeted biopsies for prostate cancer detection. DESIGN, SETTING, AND PARTICIPANTS: We used a prospective, multicenter, paired diagnostic study design. A total of 532 men aged 45-74 yr referred for prostate cancer workup were included during 2016-2017. INTERVENTION: Participants underwent blood sampling for analysis of the Stockholm3 test including protein biomarkers, genetic polymorphisms, and clinical variables; 1.5 T MRI; systematic prostate biopsies; and MRI-targeted biopsies to lesions with Prostate Imaging Reporting and Data System version 2 ≥3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The main outcome was numbers of detected prostate cancer characterized by grade group (GG) and the number of performed biopsies using relative sensitivity (RS). RESULTS AND LIMITATIONS: Median prostate-specific antigen was 6.3 ng/ml, and mean age was 63.9 yr. Targeted and systematic biopsies detected 170 and 162 GG ≥2 tumors, respectively (RS 1.05; 95% confidence interval [CI] 0.96-1.14). Compared with performing systematic biopsies on all men, performing targeted and systematic biopsies only on men with >10% risk of GG ≥2 cancer, as predicted by the Stockholm3 test, required 62% (95% CI 58-66) of the biopsy procedures and detected 58% (95% CI 48-70) of GG 1 disease, with increased sensitivity for GG ≥2 detection (RS 1.10; 95% CI 1.02-1.17). Performing only targeted biopsies in men with elevated Stockholm3 test altered these results only slightly. Compared with performing systematic and targeted biopsies on all men, performing this only for men with an elevated Stockholm3 test decreased detection of GG ≥2 cancer slightly (RS 0.92; 95% CI 0.88-0.95). Limitations include lacking knowledge of true disease prevalence. CONCLUSIONS: These findings provide evidence that strategies combining the blood-based Stockholm3 test and MRI-targeted biopsies can be used to inform biopsy decision making. PATIENT SUMMARY: In this study, 532 men coming for prostate cancer workup underwent blood sampling, and both traditional and magnetic resonance imaging/fusion-guided prostate biopsies. We report that performing targeted biopsies only in men with an elevated risk as assessed by the Stockholm3 test saved biopsies, decreased overdetection, and maintained the number of detected high-grade cancers.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Grönberg H, Eklund M, Picker W, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018. PMID: 30001824. doi:10.1016/j.eururo.2018.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。